Moderna Stock

Moderna P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Moderna (MRNA) as of Aug 1, 2026 is -8.81. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -5.49 — a change of 60.38% (lower).

P/CF

-8.81

YoY

60.38%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Moderna is 2026 -8.81 . P/CF (Price-to-Cash-Flow Ratio) of Moderna was 2025 -5.49 . It decreases by 60.38% lower compared to the previous year.
Access this data via the Eulerpool API

Moderna Stock analysis

What does Moderna do? Moderna Inc is a biotechnology company from the USA that specializes in the development of therapies and vaccines based on mRNA technology. The company was founded in 2010 by a group of researchers led by Noubar Afeyan and is headquartered in Cambridge, Massachusetts. Moderna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moderna stock

P/CF (Price-to-Cash-Flow Ratio) of Moderna is -8.81 in 2026.

Access this data via the Eulerpool API

Valuation — Moderna

All Key Metrics — Moderna